Skip to main content

Part of UT Health San Antonio

Cancer Center - UT Health San AntonioCancer Center - UT Health San Antonio

Part of UT Health San Antonio

Search

Patient Links

Give

Contact Us | 210-450-1000 800-340-2872

A Cancer Center designated by the National Cancer Institute

Patient Information

  • My Chart
  • Pay Bill Online
  • Open Clinical Trials
  • Medical Records Request
  • Insurance We Accept
  • Patient Rights & Responsibilities
  • Map / Directions / Parking
  • Living Well Newsletter

Forms

  • New Patient Information Sheet
  • Authorization for Cancer Center to Request Your Patient Health Records
  • Signature Form

 Close Quicklinks

Menu
  • Home
  • Cancer Types
  • Clinical Trials
  • Our Doctors
  • Wellness/Support
  • Research/Academics
  • Make an Appointment

You are here

  • Home
  • Home
  • Patient Care
  • Cancer Center
  • Clinical Trials
  • Open Clinical Trials

Open Clinical Trials

Filter Results

Filter List By

Results: 283 clinical trials

A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients CTMS#: 19-0035

Contact: John Sarantopoulos sarantopoulo@uthscsa.edu (210) 450-5946

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-ALL. The backbone multi-agent therapy is a modified augmented Berlin-Frankfurt-Münster (aBFM) regimen that is used in the Children's Oncology Group (COG) Study AALL1131 (control arm) for patients with de novo B-ALL. This chemotherapy backbone is the current standard of care for patients with NCI HR B-ALL. Ruxolitinib will be administered in conjunction with all post-Induction phases of the aBFM regimen.

Subjects with de novo B-ALL, aged 1 to 21 years at the time of diagnosis, will be evaluated for genetic eligibility during the Induction phase of a 4-drug regimen (modified aBFM or equivalent) received on Study AALL1131 (or its successor study) or with a similar 4-drug regimen. Genetic analysis of baseline diagnostic bone marrow aspirate or peripheral blood samples will be performed at COG ALL reference laboratories. Eligible genetic abnormalities include the following:
Rearranged CRLF2 (CRLF-R)
Mutations in JAK1 or JAK2 (JAK+)
Other alterations involving the JAK pathway (eg, JAK2 fusions, EPO-R fusions, SH2B3 deletions, IL7RA mutations)

At the end of Induction therapy, MRD will be assessed from bone marrow sampling via flow cytometric analysis, per the standard of care. For the purposes of this Protocol, end-Induction MRD status is defined as + or (-) as follows:
MRD 0.01% is MRD+
MRD < 0.01% is MRD(-)

Cohort assignment will be based upon genetic analysis and end-Induction MRD status, as follows:
Cohort A: CRLF2-R and JAK+ with MRD+
Cohort B: CRLF2-R and JAK- with MRD+
Cohort C: other JAK pathway alterations (+/- CRLF2-R) with MRD+
Cohort D: subjects otherwise eligible for Cohorts A, B, or C with MRD(-)

Contact: Anne-Marie Langevin langevin@uthscsa.edu 2105677460

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) plus First-line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC) CTMS# 19-0002

Contact: Sukeshi Arora aroras@uthscsa.edu

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201A, An Anti-HER2-Antibody Drug Conjugate, Versus Ado-Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Trea...

Contact: Virginia Kaklamani kaklamani@uthscsa.edu 2104503838

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

A research study of a new investigational (experimental) drug called VB-111 to treat advanced metastatic cancer (cancer that has spread to other parts of the body) and we want to learn if VB-111 will have a good effect on the cancer, such as keeping the cancer cells from dividing and growing. "Investigational" means that VB-111 has not been approved by the Food and Drug Administration (FDA) for commercial use, sale or marketing.

Contact: Ellen Jones jonese5@uthscsa.edu 2104505863

Pages

  • « first
  • ‹ previous
  • …
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • next ›
  • last »
Map image of UT Health location

UT Health San Antonio MD Anderson Cancer Center

7979 Wurzbach Road
San Antonio, TX 78229

210-450-1000

Stay connected

  • Facebook
  • Twitter
  • YouTube
  • About Us
  • Contact Us
  • For Researchers
  • Job Opportunities
  • Maps & Directions
  • Patient Rights and Responsibilities
  • Language Assistance
We make lives better ®

We're a part of UT Health San Antonio, provider of comprehensive health,  dental   and  cancer care,  advanced academics  and  life-saving research.

 
NCI Cancer Center. A Cancer Center Designated by the National Cancer Institute.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.